Absence of JAK-2V617F point mutations in multiple myeloma

Qin Huang(People's Hospital of Xinjiang Uygur Autonomous Region), L M Weiss(City Of Hope National Medical Center), Wei-hong Chen(City Of Hope National Medical Center), Xiangnan Li(Yancheng Third People's Hospital)
Leukemia
January 18, 2007
10.1038/sj.leu.2404551
Cited by 10

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|396
Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver.
|Journal of Biological Chemistry|1993|375
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
|Leukemia|2012|362
Immunohistochemical localization of the D1 dopamine receptor in rat brain reveals its axonal transport, pre- and postsynaptic localization, and prevalence in the basal ganglia, limbic system, and thalamic reticular nucleus.
|Proceedings of the National Academy of Sciences|1992|260